“…Effective treatments are required for COVID-19 hyperinflammatory syndrome, occurring characteristically 7-14 days after first symptoms (1) and variously described as "macrophage activation syndrome" (2), "cytokine storm" (3) or "acute respiratory distress syndrome" (4). Its immunological hallmarks are excessive elevation of predominantly proinflammatory cytokines, chemokines (5), and other bioactive molecules, such as HMGB1 (6) and reactive oxygen species (7). Upregulated cytokines include IL-6, TNF-α, IFN-γ, IL-1β, IL-15, IL-23, and IL-10, and chemokines, CXCL8(IL-8), CXCL9(MIG), CXCL10(IP10), CCL2(MCP-1), CCL3(MIP-1α), CCL5(RANTES), CCL7(MCP-3), CCL8(MCP-2), CCL11(eotaxin-1), and CCL20(MIP-3α) (1,2,(8)(9)(10)(11).…”